Loading the page…
Nasdaq 100
GEHC
GE HealthCare Technologies Inc., Health Care
$76.57
+0.20% on the day
Close of Fri, Oct 30, 2026
+12.6% over 3M
2026-07-312026-09-162026-10-30
Market cap$34.6B
Last close$76.57
Day move+0.20%
Nasdaq 100
GE HealthCare Technologies Inc., Health Care
$76.57
+0.20% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $5.7B | $5.1B | $5.0B | $4.8B | $5.3B | $4.9B | $4.8B |
| Gross margin | 38.5% | 39.7% | 38.7% | 39.6% | 42.1% | 42.8% | 41.7% | 41.4% |
| Operating margin | 10.0% | 14.5% | 12.7% | 13.1% | 13.2% | 15.1% | 13.9% | 12.6% |
| Net margin | 7.6% | 10.3% | 8.7% | 9.7% | 11.8% | 13.6% | 9.7% | 8.8% |
| EPS, diluted | $0.85 | $1.28 | $0.98 | $1.06 | $1.23 | $1.58 | $1.02 | $0.93 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | GEHC | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 5.5% | 85% |
| Book yield (book value ÷ price) | 30.6% | 81% |
| Free cash flow yield | 5.7% | 79% |
| Buyback yield | 0.6% | 45% |
| Revenue growth, a year | 4.8% | 23% |
| EPS growth, a year | 4.8% | 39% |
| Return on equity | 17.9% | 42% |
| Return on assets | 5.1% | 30% |
| Net margin | 9.1% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 24% |
| Liabilities ÷ assets | 70.6% | 75% |
|---|
| Past year, skipping last month | -17.2% | 25% |
|---|
| Past 6 months, skipping last month | 4.9% | 54% |
|---|
| Volatility, a year's worth | 25.8% | 21% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Beat the forecast in 3 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products.
From Yahoo Finance, gehealthcare.com
Picked by YouTube search, not by us. Someone else's view, not advice.
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?Zacks, Oct 29
GEHC vs. HAE: Which Stock Is the Better Value Option?Zacks, Oct 29
Mizuho Securities Adjusts GE Healthcare Technologies Price Target to $90 From $85MT Newswires, Oct 29
What Sent GE HealthCare Stock Higher?Trefis, Oct 29
GE HealthCare raises 2026 outlook after positive Q3Medical Device Network, Oct 29Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 59 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Grogan William KCFO | Award | +75,096 | — | — | Form 4 ↗ |
| Sep 14, 2026 | Grogan William KCFO | AwardEmployee Stock Option (right to buy) | +31,877 | — | — | Form 4 ↗ |
| Sep 3, 2026 | Rackliffe PhilipCEO, AIS | Tax withholding | −798 | $70.56 | $56.3K | Form 4 ↗ |
| Sep 3, 2026 | O'Neill Kevin MichaelCEO, PDx | Tax withholding | −718 | $70.56 | $50.7K | Form 4 ↗ |
| Sep 3, 2026 | Newcomb George A.CAO | Tax withholding | −112 | $70.56 | $7.9K | Form 4 ↗ |
| Sep 3, 2026 | Kass-Hout TahaCTO | Tax withholding | −1,502 | $70.56 | $106K | Form 4 ↗ |
| Sep 3, 2026 | Jimenez Frank RGC & Corporate Secretary | Tax withholding | −1,480 | $70.56 | $104K | Form 4 ↗ |
| Sep 3, 2026 | Holton Adam YChief People Officer | Tax withholding | −673 | $70.56 | $47.5K | Form 4 ↗ |
| Sep 3, 2026 | Estrampes CatherineChief Commer. & Growth Officer | Tax withholding | −508 | $70.56 | $35.8K | Form 4 ↗ |
| Sep 3, 2026 | Arduini Peter JPresident and CEO, Director | Tax withholding | −6,303 | $70.56 | $445K | Form 4 ↗ |
| Sep 1, 2026 | Rackliffe PhilipCEO, AIS | Tax withholding | −856 | $71.23 | $61K | Form 4 ↗ |
| Sep 1, 2026 | Kass-Hout TahaCTO | Tax withholding | −2,940 | $71.23 | $209K | Form 4 ↗ |
| Sep 1, 2026 | Jimenez Frank RGC & Corporate Secretary | Tax withholding | −3,131 | $71.23 | $223K | Form 4 ↗ |
| Sep 1, 2026 | Holton Adam YChief People Officer | Tax withholding | −659 | $71.23 | $46.9K | Form 4 ↗ |
| Sep 1, 2026 | Bankes JeannetteCEO, Patient Care Solutions | Tax withholding | −1,064 | $71.23 | $75.8K | Form 4 ↗ |
| Sep 1, 2026 | Arduini Peter JPresident and CEO, Director | Tax withholding | −11,515 | $71.23 | $820K | Form 4 ↗ |
| Aug 15, 2026 | Holton Adam YChief People Officer | Tax withholding | −1,360 | $73.69 | $100K | Form 4 ↗ |
| May 22, 2026 | Lobo KevinDirector | Bought on the market | +10,000 | $64.18 | $642K | Form 4 ↗ |
| May 15, 2026 | Rackliffe PhilipCEO, AIS | Award | +16,458 | — | — | Form 4 ↗ |
| May 15, 2026 | Bankes JeannetteCEO, Patient Care Solutions | Tax withholding | −5,535 | $62.67 | $347K | Form 4 ↗ |
| May 12, 2026 | Hochman Rodney FDirector | Bought on the market | +1,618 | $62.03 | $100K | Form 4 ↗ |
| May 8, 2026 | Yang Watkin Phoebe L.Director | Bought on the market | +1,000 | $63.01 | $63K | Form 4 ↗ |
| May 7, 2026 | Yang Watkin Phoebe L.Director | Award | +3,586 | — | — | Form 4 ↗ |
| May 7, 2026 | Culp H Lawrence JrDirector | Award | +7,743 | — | — | Form 4 ↗ |
| May 7, 2026 | Hochman Rodney FDirector | Award | +6,275 | — | — | Form 4 ↗ |
| May 7, 2026 | Lesjak Catherine ADirector | Award | +3,586 | — | — | Form 4 ↗ |
| May 7, 2026 | Lobo KevinDirector | Award | +3,586 | — | — | Form 4 ↗ |
| May 7, 2026 | Madden Anne TDirector | Award | +5,868 | — | — | Form 4 ↗ |
| May 7, 2026 | Stromberg William JDirector | Award | +3,586 | — | — | Form 4 ↗ |
| May 6, 2026 | Culp H Lawrence JrDirector | Bought on the market | +80,805 | $61.88 | $5.0M | Form 4 ↗ |
| May 6, 2026 | Stromberg William JDirector | Bought on the market | +1,000 | $61.69 | $61.7K | Form 4 ↗ |
| May 1, 2026 | Saccaro JamesCFO | Bought on the market | +3,310 | $60.60 | $201K | Form 4 ↗ |
| Apr 30, 2026 | Jimenez Frank RGC & Corporate Secretary | Bought on the market | +1,750 | $60.45 | $106K | Form 4 ↗ |
| Apr 30, 2026 | Arduini Peter JPresident and CEO, Director | Bought on the market | +4,169 | $59.93 | $250K | Form 4 ↗ |
| Mar 13, 2026 | Lobo KevinDirector | Award | +777 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Bankes JeannetteCEO, Patient Care Solutions | Award | +6,861 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Bankes JeannetteCEO, Patient Care Solutions | AwardEmployee Stock Option (right to buy) | +18,038 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Jimenez Frank RGC & Corporate Secretary | Award | +10,915 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Jimenez Frank RGC & Corporate Secretary | AwardEmployee Stock Option (right to buy) | +28,697 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Kass-Hout TahaCTO | Award | +13,254 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Kass-Hout TahaCTO | AwardEmployee Stock Option (right to buy) | +34,847 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Holton Adam YChief People Officer | Award | +5,457 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Holton Adam YChief People Officer | AwardEmployee Stock Option (right to buy) | +14,348 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Newcomb George A.CAO | Award | +1,309 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Newcomb George A.CAO | AwardEmployee Stock Option (right to buy) | +3,443 | — | — | Form 4 ↗ |
| Mar 2, 2026 | O'Neill Kevin MichaelCEO, PDx | Award | +6,549 | — | — | Form 4 ↗ |
| Mar 2, 2026 | O'Neill Kevin MichaelCEO, PDx | AwardEmployee Stock Option (right to buy) | +17,218 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Rackliffe PhilipCEO, AVS | Award | +9,356 | — | — | Form 4 ↗ |
| Mar 2, 2026 | Rackliffe PhilipCEO, AVS | AwardEmployee Stock Option (right to buy) | +24,598 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 59 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?Zacks, Oct 29GEHC vs. HAE: Which Stock Is the Better Value Option?Zacks, Oct 29Mizuho Securities Adjusts GE Healthcare Technologies Price Target to $90 From $85MT Newswires, Oct 29What Sent GE HealthCare Stock Higher?Trefis, Oct 29GE HealthCare raises 2026 outlook after positive Q3Medical Device Network, Oct 29RBC Raises Price Target on GE Healthcare Technologies to $90 From $80, Keeps Outperform RatingMT Newswires, Oct 29Rothschild & Co Redburn Adjusts Price Target on GE Healthcare Technologies to $100 From $96MT Newswires, Oct 29BNP Paribas Adjusts Price Target on GE Healthcare Technologies to $100 From $96MT Newswires, Oct 29
GE Vernova Places High-Voltage, $9 Billion Bet on Energy EquipmentThe Daily Upside, Oct 29
GE HealthCare Technologies Q3 Earnings Call HighlightsMarketBeat, Oct 29Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance